SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    J. Hugosson, G. Aus, S. Bergdahl, P. Fernlund, R. Frösing, P. Lodding, C.-G. Pihl, H. Lilja, Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden, BJU International, 2003, 92,
  2. 2
    C.A Mochtar, L.A.L.M Kiemeney, M.M van Riemsdijk, G.S Barnett, M.P Laguna, F.M.J Debruyne, J.J.M.C.H de la Rosette, Prostate-Specific Antigen as an Estimator of Prostate Volume in the Management of Patients with Symptomatic Benign Prostatic Hyperplasia, European Urology, 2003, 44, 6, 695

    CrossRef

  3. 3
    RICHARD J. BABAIAN, DENNIS A. JOHNSTON, WILLIAM NACCARATO, ALBERTO AYALA, VIJAYA A. BHADKAMKAR, HERBERT A. FRITSCHE, THE INCIDENCE OF PROSTATE CANCER IN A SCREENING POPULATION WITH A SERUM PROSTATE SPECIFIC ANTIGEN BETWEEN 2.5 AND 4.0 NG./ML.: RELATION TO BIOPSY STRATEGY, The Journal of Urology, 2001, 757

    CrossRef

  4. 4
    RICHARD J. BABAIAN, DENNIS A. JOHNSTON, WILLIAM NACCARATO, ALBERTO AYALA, VIJAYA A. BHADKAMKAR, HERBERT A. FRITSCHE, THE INCIDENCE OF PROSTATE CANCER IN A SCREENING POPULATION WITH A SERUM PROSTATE SPECIFIC ANTIGEN BETWEEN 2.5 AND 4.0 NG./ML.: RELATION TO BIOPSY STRATEGY, The Journal of Urology, 2001, 165, 3, 757

    CrossRef

  5. You have free access to this content5
    Yuzo Furuya, Koichiro Akakura, Toyofusa Tobe, Tomohiko Ichikawa, Tatsuo Igarashi, Haruo Ito, Changes in serum prostate-specific antigen following prostatectomy in patients with benign prostate hyperplasia, International Journal of Urology, 2000, 7, 12
  6. 6
    Philip C. Prorok, Gerald L. Andriole, Robert S. Bresalier, Saundra S. Buys, David Chia, E. David Crawford, Ronald Fogel, Edward P. Gelmann, Fred Gilbert, Marsha A. Hasson, Richard B. Hayes, Christine Cole Johnson, Jack S. Mandel, Albert Oberman, Barbara O'Brien, Martin M. Oken, Sameer Rafla, Douglas Reding, Wilmer Rutt, Joel L. Weissfeld, Lance Yokochi, John K. Gohagan, Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial, Controlled Clinical Trials, 2000, 21, 6, 273S

    CrossRef

  7. 7
    R.Joseph Babaian, Herbert Fritsche, Alberto Ayala, Vijaya Bhadkamkar, Dennis A Johnston, William Naccarato, Zhen Zhang, Performance of a neural network in detecting prostate cancer in the prostate-specific antigen reflex range of 2.5 to 4.0 ng/mL, Urology, 2000, 56, 6, 1000

    CrossRef

  8. 8
    Peter J. Littrup, Sharlene E. Bailey, PROSTATE CANCER: THE ROLE OF TRANSRECTAL ULTRASOUND AND ITS IMPACT ON CANCER DETECTION AND MANAGEMENT, Radiologic Clinics of North America, 2000, 38, 1, 87

    CrossRef

  9. 9
    K PerezNiddam, Economic evaluation of a prostate cancer screening program in France: a decision model, Critical Reviews in Oncology/Hematology, 1999, 32, 2, 167

    CrossRef

  10. 10
    Alvaro L Ronco, Rossana Fernandez, Improving ultrasonographic diagnosis of prostate cancer with neural networks, Ultrasound in Medicine & Biology, 1999, 25, 5, 729

    CrossRef

  11. You have free access to this content11
    Wataru Sakamoto, Hironori Iwata, Sadanori Kamikawa, Kiyoshi Tsurusaki, Toshikado Sugimoto, Tatsuya Nakatani, Kazunobu Sugimura, Keisuke Yamamoto, Taketoshi Kishimoto, Role of the Transition Zone for Elevating Serum Prostate-Specific Antigen in Benign Prostatic Hyperplasia, International Journal of Urology, 1998, 5, 2
  12. 12
    Ch. Deliveliotis, G. Louras, P. Kyriazis, A. Gyftopoulos, L. Louka, E. Alargof, The value of prostatic specific antigen density in the early diagnosis of prostate cancer, International Urology and Nephrology, 1998, 30, 3, 305

    CrossRef

  13. 13
    Sally P. Weinrich, Martin Weinrich, Curtis Mettlin, William A. Reynolds, John E. Wofford, Urinary symptoms as a predictor for participation in prostate cancer screening among African American men, The Prostate, 1998, 37, 4
  14. 14
    Thomas H. Douglas, Ted O. Morgan, David G. McLeod, Judd W. Moul, Gerald P. Murphy, Robert Barren, Isabell A. Sesterhenn, Fathollah K. Mostofi, Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients, Cancer, 1997, 80, 1
  15. 15
    Richard J. Babaian, Current status of enhancing the detection of prostate cancer, The Prostate, 1997, 31, 3
  16. 16
    R. Clements, The changing role of transrectal ultrasound in the diagnosis of prostate cancer, Clinical Radiology, 1996, 51, 10, 671

    CrossRef

  17. 17
    Curtis Mettlin, Gerald P. Murphy, Richard J. Babaian, Arthur Chesley, Robert A. Kane, Peter J. Littrup, Fatoullah K. Mostofi, Paul S. Ray, Allen M. Shanberg, Ants Toi, The results of a five-year early prostate cancer detection intervention, Cancer, 1996, 77, 1
  18. 18
    Curtis Mettlin, American cancer society national prostate cancer detection project. Goals and current status, Cancer, 1995, 75, S7
  19. 19
    J. L. H. Ruud Bosch, Wim C. J. Hop, Chris H. Bangma, Wim J. Kirkels, Fritz H. Schröder, Prostate specific antigen in a community-based sample of men without prostate cancer: Correlations with prostate volume, age, body mass index, and symptoms of prostatism, The Prostate, 1995, 27, 5
  20. 20
    Christopher M. Coley, Michael J. Barry, Craig Fleming, John H. Wasson, Marianne C. Fahs, Joseph E. Oesterling, Should medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part II: Early detection strategies, Urology, 1995, 46, 2, 125

    CrossRef

  21. 21
    Peter J. Littrup, Ronald Sparschu, Transrectal ultrasound and prostate cancer risks. The “tailored” prostate biopsy, Cancer, 1995, 75, S7
  22. 22
    Peter J. Littrup, Robert A. Kane, Curtis J. Mettlin, Gerald P. Murphy, Fred Lee, Ants Toi, Robert Badalament, Richard Babaian, Cost-effective prostate cancer detection. Reduction of low-yield biopsies, Cancer, 1994, 74, 12
  23. 23
    Peter J. Littrup, Prostate cancer screening. Appropriate choices?, Cancer, 1994, 74, S7
  24. 24
    C.Norman Coleman, Clair J. Beard, Philip W. Kantoff, Rebecca Gelman, Rate of relapse following treatment for localized prostate cancer: A critical analysis of retrospective reports, International Journal of Radiation Oncology*Biology*Physics, 1994, 28, 1, 303

    CrossRef

  25. 25
    Curtis Mettlin, Peter J. Littrup, Robert A. Kane, Gerald P. Murphy, Fred Lee, Arthur Chesley, Robert Badalament, Fatollah K. Mostofi, Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density, and PSA change, Cancer, 1994, 74, 5
  26. 26
    Peter Reizenstein, Baruch Modan, Lewis H. Kuller, The quandary of cancer prevention, Journal of Clinical Epidemiology, 1994, 47, 6, 575

    CrossRef

  27. 27
    Curtis Mettlin, Gerald P. Murphy, Paul Ray, Allan Shanberg, Ants Toi, Arthur Chesley, Richard Babaian, Robert Badalament, Robert A. Kane, Fred Lee, American cancer society–national prostate cancer detection project. Results from multiple examinations using transrectal ultrasound, digital rectal examination, and prostate specific antigen, Cancer, 1993, 71, S3
  28. 28
    Linda N. White, Margaret R. Spitz, Cancer risk and early detection assessment, Seminars in Oncology Nursing, 1993, 9, 3, 188

    CrossRef

  29. 29
    Curtis Mettlin, Gerald P. Murphy, Fred Lee, Peter J. Littrup, Arthur Chesley, Richard Babaian, Robert Badalament, Robert A. Kane, F. K. Mostofi, Characteristics of prostate cancers detected in a multimodality early detection program, Cancer, 1993, 72, 5
  30. 30
    Douglas C. Aziz, Raj B. Barathur, Prostate-specific antigen and prostate volume: A meta-analysis of prostate cancer screening criteria, Journal of Clinical Laboratory Analysis, 1993, 7, 5
  31. 31
    Curtis Mettlin, The status of prostate cancer early detection, Cancer, 1993, 72, S3
  32. 32
    Fred Lee, Peter J. Littrup, The role of digital rectal examination, transrectal ultrasound, and prostate specific antigen for the detection of confined and clinically relevant prostate cancer, Journal of Cellular Biochemistry, 1992, 50, S16H